Intellia Therapeutics NTLA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

ALN

Alnylam PharmaceuticalsALNY

$45.93M-0.4%

CRISPR TherapeuticsCRSP

$18.61M+6.3%

Beam TherapeuticsBEAM

$14.78M+11.9%

Design Therapeutics, Inc.DSGN

$536K-34.7%

Prime MedicinePRME

$8.97M+23.6%

Iovance Biotherapeutics, Inc.IOVA

$2.67M-62.2%

FAQ

What is Intellia Therapeutics's operating lease liabilities (current)?

Intellia Therapeutics (NTLA) reported operating lease liabilities (current) of $23.34M in Q2 2026.

How has Intellia Therapeutics's operating lease liabilities (current) changed year-over-year?

Intellia Therapeutics's operating lease liabilities (current) decreased by 13.5% year-over-year, from $26.99M to $23.34M.

What is the long-term trend for Intellia Therapeutics's operating lease liabilities (current)?

Over 5 years (2020 to 2025), Intellia Therapeutics's operating lease liabilities (current) has grown at a 36.0% compound annual growth rate (CAGR), from $5.7M to $26.48M.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.